Pfizer announces Phase 3 study results of LYRICA Oral Solution CV for pediatric epilepsy patients

May 17, 2018 GOSCIN 0Comments

Pfizer Inc. announced today positive top-line results of a Phase 3 study examining the use of LYRICA® Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age.

from News-Medical.Net Spinal Cord Injury News Feed

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.